Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide

Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.

Kiran Mazumdar-Shaw said Biocon delivered a strong revenue growth of 35 per cent this quarter, driven by robust performance across our biologics, small molecules and research services segments.

Ogivri is the first United States Food and Drug Administration (USFDA) approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US, the two companies said in a joint statement.